LIVIVO - Search results -

Search results

Result 1 - 10 of total 382

Search options

Article: Guide illustré pour l’observation du comportement sensori-moteur du nouveau-né prématuré.

Rossi Jelidi, Mireille / Vandenbroucke, Valérie / Martinet, Myrtha / Rioual, Roxane / Borradori Tolsa, Cristina / Sizonenko, Stéphane / E Pfister, Riccardo

Soins. Pediatrie, puericulture

2022 Volume 43, Issue 328, Page(s) 39–45

Abstract: Developmental care is defined by a personalized approach to the premature child. Observation of sensory-motor behavior is a key part of this approach and requires specific training and the use of observation tools. This study analyzes the use of an ... ...

Title translation	"Illustrated guide for the observation of the sensory-motor behavior of the preterm newborn".
Abstract	Developmental care is defined by a personalized approach to the premature child. Observation of sensory-motor behavior is a key part of this approach and requires specific training and the use of observation tools. This study analyzes the use of an illustrated guide during the observation and evaluation of the sensory-motor behavior of the premature baby; this didactic contribution constitutes a real added value for the professionals, allowing the elaboration of a care project.
MeSH term(s)	Child ; Child, Hospitalized ; Family ; Female ; Humans ; Infant ; Infant, Newborn ; Infant, Premature, Diseases ; Premature Birth
Language	French
Publishing date	2022-07-20
Publishing country	France
Document type	Journal Article ; Review
ZDB-ID	1234484-9
ISSN	2214-9325 ; 1259-4792
ISSN (online)	2214-9325
ISSN	1259-4792
DOI	10.1016/j.spp.2022.07.013
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2788: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Rituximab and risk of infections in patients with pemphigus: answers from a global population-based cohort study.

Cazzaniga, Simone / Naldi, Luigi / Borradori, Luca

The British journal of dermatology

2023 Volume 188, Issue 4, Page(s) 454–455

MeSH term(s)	Humans ; Rituximab/adverse effects ; Pemphigus/drug therapy ; Pemphigus/epidemiology ; Cohort Studies ; Azathioprine ; Mycophenolic Acid ; Treatment Outcome
Chemical Substances	Rituximab (4F4X42SYQ6) ; Azathioprine (MRK240IY2L) ; Mycophenolic Acid (HU9DX48N0T)
Language	English
Publishing date	2023-01-31
Publishing country	England
Document type	Editorial ; Comment
ZDB-ID	80076-4
ISSN	1365-2133 ; 0007-0963
ISSN (online)	1365-2133
ISSN	0007-0963
DOI	10.1093/bjd/ljad005
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.23: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Pool Toes: A Case Report.

Munshi, Mohammad / Borradori, Luca / Yawalkar, Nikhil / Heidemeyer, Kristine

Case reports in dermatology

2023 Volume 15, Issue 1, Page(s) 31–34

Abstract: Pool toes, a sport-related dermatosis, are caused by mechanical friction and water exposure, resulting in a special variant of irritant contact dermatitis. It is common in children, often misdiagnosed, and rarely reported. Here we report a case of a 7- ... ...

Abstract	Pool toes, a sport-related dermatosis, are caused by mechanical friction and water exposure, resulting in a special variant of irritant contact dermatitis. It is common in children, often misdiagnosed, and rarely reported. Here we report a case of a 7-year-old girl who developed this unusual type of frictional dermatitis; a pool toes diagnosis has been made. With topical corticosteroids, favorable results have been achieved. The recovery and healing process will be facilitated if one is aware of the underlying causes of such dermatitis and ceases the triggering factors.
Language	English
Publishing date	2023-02-03
Publishing country	Switzerland
Document type	Case Reports
ZDB-ID	2505300-0
ISSN	1662-6567
ISSN	1662-6567
DOI	10.1159/000529079
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors.

Mita, M / Gordon, M / Rejeb, N / Gianella-Borradori, A / Jego, V / Mita, A / Sarantopoulos, J / Sankhala, K / Mendelson, D

Targeted oncology

2013 Volume 9, Issue 3, Page(s) 215–224

Abstract: Aurora kinase inhibitors (AKIs) are a class of antimitotic, small-molecule anticancer agents. MSC1992371A is an AKI being evaluated for the treatment of patients with solid tumors. This phase I, open-label, dose-escalation study determined the maximum ... ...

Abstract	Aurora kinase inhibitors (AKIs) are a class of antimitotic, small-molecule anticancer agents. MSC1992371A is an AKI being evaluated for the treatment of patients with solid tumors. This phase I, open-label, dose-escalation study determined the maximum tolerated dose (MTD) of MSC1992371A in different dosing schedules in patients with locally advanced or metastatic solid tumors. MSC1992371A was administered on days 1 and 8 (schedule 1) or on days 1, 2, and 3 (schedule 2) of a 21-day cycle. The study was expanded with a third schedule (study drug on days 1-3 and 8-10). Adverse events were monitored throughout the study. Antitumor efficacy, drug pharmacokinetics, and pharmacodynamics were evaluated. Ninety-two patients were enrolled. MSC1992371A was dosed over eight levels in schedules 1 and 2, and the MTD was determined as 74 mg/m(2) per cycle for both schedules and as 60 mg/m(2) in schedule 3, albeit only in three patients due to discontinuation of the study. Overall, the most common grade 3 or 4 treatment-emergent adverse events were neutropenia, febrile neutropenia, thrombocytopenia, anemia, and fatigue. The most frequent dose-limiting toxicity over all schedules was neutropenia. MSC1992371A plasma concentrations tended to increase with increasing dose levels. Although no complete or partial responses were seen, stable disease ≥3 months was observed in 11 patients. Analysis for markers of target modulation and pharmacodynamics effects was unsuccessful. MSC1992371A was generally well tolerated in patients, with mainly transient hematologic toxicities apparent at an MTD of 60-74 mg/m(2)/21-day cycle, independent of dosing frequency.
MeSH term(s)	Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Aurora Kinase A/antagonists & inhibitors ; Cohort Studies ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Food-Drug Interactions ; Humans ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neoplasm Metastasis ; Neoplasms/drug therapy ; Neoplasms/metabolism ; Neoplasms/pathology ; Norbornanes/administration & dosage ; Norbornanes/adverse effects ; Norbornanes/pharmacokinetics ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/pharmacokinetics ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Pyrimidines/pharmacokinetics ; Treatment Outcome ; Young Adult
Chemical Substances	MSC1992371A ; Norbornanes ; Protein Kinase Inhibitors ; Pyrimidines ; Aurora Kinase A (EC 2.7.11.1)
Language	English
Publishing date	2013-07-06
Publishing country	France
Document type	Clinical Trial, Phase I ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	2222136-0
ISSN	1776-260X ; 1776-2596
ISSN (online)	1776-260X
ISSN	1776-2596
DOI	10.1007/s11523-013-0288-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Deciphering the Contribution of BP230 Autoantibodies in Bullous Pemphigoid.

Cole, Connor / Borradori, Luca / Amber, Kyle T

Antibodies (Basel, Switzerland)

2022 Volume 11, Issue 3

Abstract: Bullous pemphigoid (BP) is a subepidermal autoimmune blistering disease predominantly affecting elderly patients and carries significant morbidity and mortality. Patients typically suffer from severe itch with eczematous lesions, urticarial plaques, and/ ... ...

Abstract	Bullous pemphigoid (BP) is a subepidermal autoimmune blistering disease predominantly affecting elderly patients and carries significant morbidity and mortality. Patients typically suffer from severe itch with eczematous lesions, urticarial plaques, and/or tense blisters. BP is characterized by the presence of circulating autoantibodies against two components of the hemidesmosome, BP180 and BP230. The transmembrane BP180, also known as type XVII collagen or BPAG2, represents the primary pathogenic autoantigen in BP, whereas the intracellular BP230 autoantigen is thought to play a minor role in disease pathogenesis. Although experimental data exist suggesting that anti-BP230 antibodies are secondarily formed following initial tissue damage mediated by antibodies targeting extracellular antigenic regions of BP180, there is emerging evidence that anti-BP230 IgG autoantibodies alone directly contribute to tissue damage. It has been further claimed that a subset of patients has a milder variant of BP driven solely by anti-BP230 autoantibodies. Furthermore, the presence of anti-BP230 autoantibodies might correlate with distinct clinical features. This review summarizes the current understanding of the role of BP230 and anti-BP230 antibodies in BP pathogenesis.
Language	English
Publishing date	2022-06-28
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2661514-9
ISSN	2073-4468 ; 2073-4468
ISSN (online)	2073-4468
ISSN	2073-4468
DOI	10.3390/antib11030044
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Pterygium in bullous pemphigoid: An unusual complication.

Haneke, Eckart / Borradori, Luca

JAAD case reports

2020 Volume 6, Issue 8, Page(s) 737–739

Language	English
Publishing date	2020-06-04
Publishing country	United States
Document type	Case Reports
ZDB-ID	2834220-3
ISSN	2352-5126
ISSN	2352-5126
DOI	10.1016/j.jdcr.2020.05.026
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Neutrophilic dermatosis of the dorsal hands triggered by mechanical trauma.

Gloor, A D / Feldmeyer, L / Borradori, L

Journal of the European Academy of Dermatology and Venereology : JEADV

2020 Volume 35, Issue 1, Page(s) e20–e21

MeSH term(s)	Hand ; Hand Dermatoses/etiology ; Humans ; Leukocyte Disorders ; Neutrophils ; Sweet Syndrome/diagnosis ; Sweet Syndrome/etiology
Language	English
Publishing date	2020-07-21
Publishing country	England
Document type	Letter
ZDB-ID	1128828-0
ISSN	1468-3083 ; 0926-9959
ISSN (online)	1468-3083
ISSN	0926-9959
DOI	10.1111/jdv.16750
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3492: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 413: Show issues

Order via subito

Details ▾

Article ; Online: Oral Acitretin Plus Topical Triamcinolone vs Topical Triamcinolone Monotherapy in Patients With Symptomatic Oral Lichen Planus: A Randomized Clinical Trial.

Vinay, Keshavamurthy / Kumar, Sheetanshu / Dev, Anubha / Cazzaniga, Simone / Borradori, Luca / Thakur, Vishal / Dogra, Sunil

JAMA dermatology

2023 Volume 160, Issue 1, Page(s) 80–87

Abstract: Importance: Symptomatic oral lichen planus (OLP) can be challenging to treat.: Objective: To compare the efficacy of oral acitretin plus topical triamcinolone acetonide (TAC), 0.1%, with TAC monotherapy in patients with symptomatic OLP.: Design, ... ...

Abstract	Importance: Symptomatic oral lichen planus (OLP) can be challenging to treat. Objective: To compare the efficacy of oral acitretin plus topical triamcinolone acetonide (TAC), 0.1%, with TAC monotherapy in patients with symptomatic OLP. Design, setting, and participants: This monocentric, investigator-initiated, placebo-controlled, investigator- and patient-blinded randomized clinical trial was conducted from December 2018 to June 2020 at the Postgraduate Institute of Medical Education and Research, a tertiary referral center in Chandigarh, India. Sixty-four patients 18 years or older with symptomatic OLP were recruited by consecutive sampling. Data were analyzed from July to December 2020. Intervention: The patients were randomized to receive either a combination of oral acitretin (25-35 mg/d) and TAC (treatment group) or TAC in combination with placebo (placebo group) for 28 weeks, with an additional 8 weeks of treatment-free follow-up after the end of treatment (36 weeks of total study duration). Main outcomes and measures: The disease severity and treatment response were assessed using Oral Disease Severity Score (ODSS), Oral Health Impact Profile 14 (OHIP-14), and visual analog scale (VAS). The primary aim was to assess the number of patients achieving ODSS-75 (75% reduction in ODSS compared with baseline) in both groups at 28 weeks and at the end of 36 weeks. Results: Among 64 patients, 31 in the treatment group and 30 in the placebo group completed the study (mean [SD] age, 50.6 [15.2] years vs 49.2 [14.4] years; male-female ratio, 13:19 vs 16:16). Baseline ODSS, visual analog scale, and Oral Health Impact Profile 14 scores were comparable in both groups. In the intention-to-treat analysis, there was a statistically significant higher number of patients achieving 75% or higher reduction in ODSS in the treatment group compared with the placebo group at the end of 28 weeks (28 [88%] vs 15 [47%], a 41 [95% CI, 20-61] percentage point difference between groups; P < .001; Cramér V = 0.47) and 36 weeks (27 [84%] vs 13 [41%], a 43 [95% CI, 23-67] percentage point difference between groups; P < .001; Cramér V = 0.47). Relapses during the posttreatment follow-up of 8 weeks were low among patients in both treatment and placebo groups (1 [3%] vs 2 [6%], a 3 [95% CI, -13 to 7] percentage point difference between groups; P > .99; Cramér V = 0.07). Conclusion and relevance: In this randomized clinical trial, the combination of oral acitretin and TAC was more effective than TAC monotherapy in patients with symptomatic OLP. Trial registration: Clinical Trial Registry of India Identifier: CTRI/2018/11/016448.
MeSH term(s)	Female ; Humans ; Male ; Middle Aged ; Acitretin/therapeutic use ; Glucocorticoids ; India ; Lichen Planus, Oral/drug therapy ; Triamcinolone Acetonide/therapeutic use ; Adult ; Aged
Chemical Substances	Acitretin (LCH760E9T7) ; Glucocorticoids ; Triamcinolone Acetonide (F446C597KA)
Language	English
Publishing date	2023-12-06
Publishing country	United States
Document type	Randomized Controlled Trial ; Journal Article
ZDB-ID	2701761-8
ISSN	2168-6084 ; 2168-6068
ISSN (online)	2168-6084
ISSN	2168-6068
DOI	10.1001/jamadermatol.2023.4889
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.32: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Insights Into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms.

Cole, Connor / Vinay, Keshavamurthy / Borradori, Luca / Amber, Kyle T

Frontiers in immunology

2022 Volume 13, Page(s) 912876

Abstract: Bullous pemphigoid is an autoimmune blistering disease caused by autoantibodies targeting BP180 and BP230. While deposits of IgG and/or complement along the epidermal basement membrane are typically seen suggesting complement -mediated pathogenesis, ... ...

Abstract	Bullous pemphigoid is an autoimmune blistering disease caused by autoantibodies targeting BP180 and BP230. While deposits of IgG and/or complement along the epidermal basement membrane are typically seen suggesting complement -mediated pathogenesis, several recent lines of evidence point towards complement-independent pathways contributing to tissue damage and subepidermal blister formation. Notable pathways include macropinocytosis of IgG-BP180 complexes resulting in depletion of cellular BP180, direct induction of pro-inflammatory cytokines from keratinocytes, as well as IgE autoantibody- and eosinophil-mediated effects. We review these mechanisms which open new perspectives on novel targeted treatment modalities.
MeSH term(s)	Autoantibodies ; Autoantigens ; Autoimmune Diseases ; Blister ; Complement System Proteins ; Humans ; Immunoglobulin G ; Pemphigoid, Bullous
Chemical Substances	Autoantibodies ; Autoantigens ; Immunoglobulin G ; Complement System Proteins (9007-36-7)
Language	English
Publishing date	2022-07-07
Publishing country	Switzerland
Document type	Journal Article ; Review ; Research Support, N.I.H., Extramural
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2022.912876
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Outcome and long-term treatment protocol for topical tacrolimus in oral lichen planus.

Utz, S / Suter, V G A / Cazzaniga, S / Borradori, L / Feldmeyer, L

Journal of the European Academy of Dermatology and Venereology : JEADV

2022 Volume 36, Issue 12, Page(s) 2459–2465

Abstract: Background and objective: Topical tacrolimus has been shown to be beneficial in the treatment of oral lichen planus (OLP). However, long-term effects and its optimal application protocol with gradual reduction have not been studied. Accordingly, we ... ...

Abstract	Background and objective: Topical tacrolimus has been shown to be beneficial in the treatment of oral lichen planus (OLP). However, long-term effects and its optimal application protocol with gradual reduction have not been studied. Accordingly, we analysed the clinical response of OLP to tacrolimus in our daily clinical practice with a focus on the optimal long-term therapeutic scheme. Methods: Retrospective analysis of all consecutive patients diagnosed with OLP and treated with topical tacrolimus (0.03% oral rinse) in a clinical setting between 2015 and 2020. The objective clinical response was measured by a 4-point scale (complete remission, major remission, partial remission and no response), and subjective impairment by a 3-point scale (severe, moderate and none). Results: Fifty-seven patients (74% women; median age: 66 years) were included. Fifty-six (98%) patients had prior treatment with topical steroids. After introduction of tacrolimus, objective remission (major or complete) was reached by 28%, 62%, 87% and 97% of patients after 3, 6, 12 and 24 months respectively. Subjective remission was reported by 16%, 48%, 69% and 83% after 3, 6, 12 and 24 months of treatment respectively. The treatment frequency could be gradually reduced from initially twice daily to once daily or less in 28%, 61%, 78% and 87% after 3, 6, 12 and 24 months respectively; 41% of patients completely suspended the treatment at one point, but 67% of them experienced a relapse after a median time of 3.3 months. Four patients (7%) developed a squamous cell carcinoma (SCC) during the observation period. Otherwise, there were only few and minor side-effects. Conclusion: Topical tacrolimus can be an effective second-line therapy for OLP refractory to potent topical corticosteroids. The therapy frequency can often be reduced during the maintenance period. Both signs of clinical activity and subjective impairment should guide therapy. Regular follow-up is necessary to recognize possible SCC.
MeSH term(s)	Humans ; Female ; Aged ; Male ; Tacrolimus ; Lichen Planus, Oral/drug therapy ; Lichen Planus, Oral/pathology ; Retrospective Studies ; Immunosuppressive Agents/therapeutic use ; Administration, Topical ; Treatment Outcome ; Neoplasm Recurrence, Local/drug therapy ; Carcinoma, Squamous Cell/drug therapy ; Clinical Protocols
Chemical Substances	Tacrolimus (WM0HAQ4WNM) ; Immunosuppressive Agents
Language	English
Publishing date	2022-08-03
Publishing country	England
Document type	Journal Article
ZDB-ID	1128828-0
ISSN	1468-3083 ; 0926-9959
ISSN (online)	1468-3083
ISSN	0926-9959
DOI	10.1111/jdv.18457
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3492: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 413: Show issues

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito